C17 Stock Overview
A clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Corvus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.76 |
| 52 Week High | US$9.00 |
| 52 Week Low | US$1.22 |
| Beta | 1.04 |
| 11 Month Change | 12.14% |
| 3 Month Change | 111.16% |
| 1 Year Change | 525.81% |
| 33 Year Change | 158.67% |
| 5 Year Change | 185.29% |
| Change since IPO | -39.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| C17 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.0% | 0.8% | -1.3% |
| 1Y | 525.8% | -17.5% | 7.4% |
Return vs Industry: C17 exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: C17 exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| C17 volatility | |
|---|---|
| C17 Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C17's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: C17's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 28 | Rick Miller | www.corvuspharma.com |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer.
Corvus Pharmaceuticals, Inc. Fundamentals Summary
| C17 fundamental statistics | |
|---|---|
| Market cap | €491.71m |
| Earnings (TTM) | -€54.22m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.8x
P/E RatioIs C17 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C17 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$56.83m |
| Earnings | -US$56.83m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did C17 perform over the long term?
See historical performance and comparison